Milestone Scientific price to book ratio MLSS
Market value divided by the book value of the company's net assets, since 2011.
- Today, Oct 23, 2026
- 7.8×
- 10-year median
- 7.5×
- Against its 10-year history
- 54th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 2.7× to 175×
- Peer median
- 1.9×
Milestone Scientific's price to book ratio is 7.8× as of Oct 23, 2026.
That is above its ten-year median of 7.5×, close to the middle of its last ten years.
Over that time it ranged from 2.7× in Mar 2018 to 175× in Jun 2020.
The median for 5 medical instruments and supplies stocks of a similar size is 1.9×.
Price to book ratio over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 7.8× | 7.6× | 18.5× |
| 2025 | 8.9× | 7.6× | 17.5× |
| 2024 | 9.5× | 5.3× | 10.8× |
| 2023 | 6.8× | 3.3× | 9.7× |
| 2022 | 2.9× | 2.8× | 8.8× |
| 2021 | 8.6× | 5.7× | 18.2× |
| 2020 | 8.5× | 5.3× | 175× |
| 2019 | 60.0× | 4.9× | 73.6× |
| 2018 | 11.4× | 2.7× | 20.4× |
| 2017 | 4.4× | 3.7× | 6.5× |
| 2016 | 5.6× | 2.8× | 8.4× |
| 2015 | 4.5× | 3.3× | 6.0× |
| 2014 | 3.4× | 2.6× | 8.5× |
| 2013 | 7.5× | 6.6× | 13.7× |
| 2012 | 10.7× | 2.1× | 10.8× |
| 2011 | 2.6× | 2.2× | 45.2× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Milestone Scientific's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| MLSSMilestone Scientific | 7.8× |
| NEPHNephros | 3.2× |
| APTAlpha Pro Tech | 0.9× |
| KEQUKewaunee Scientific | 1.3× |
| PDEXPro DEX | 4.2× |
| UTMDUtah Medical Products | 1.9× |
| Peer median | 1.9× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Milestone Scientific
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.